Free Trial

Immix Biopharma (IMMX) Competitors

Immix Biopharma logo
$2.41 +0.32 (+15.31%)
Closing price 04:00 PM Eastern
Extended Trading
$2.02 -0.39 (-16.14%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMMX vs. FHTX, PROK, ADCT, RZLT, ANNX, NVCT, AARD, AMRN, MNPR, and DRUG

Should you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Foghorn Therapeutics (FHTX), ProKidney (PROK), ADC Therapeutics (ADCT), Rezolute (RZLT), Annexon (ANNX), Nuvectis Pharma (NVCT), Aardvark Therapeutics (AARD), Amarin (AMRN), Monopar Therapeutics (MNPR), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry.

Immix Biopharma vs.

Immix Biopharma (NASDAQ:IMMX) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations.

Foghorn Therapeutics received 36 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 66.20% of users gave Foghorn Therapeutics an outperform vote.

CompanyUnderperformOutperform
Immix BiopharmaOutperform Votes
11
100.00%
Underperform Votes
No Votes
Foghorn TherapeuticsOutperform Votes
47
66.20%
Underperform Votes
24
33.80%

Immix Biopharma has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -357.53%. Foghorn Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Immix BiopharmaN/A -102.68% -80.89%
Foghorn Therapeutics -357.53%N/A -30.98%

Immix Biopharma currently has a consensus target price of $7.00, suggesting a potential upside of 186.89%. Foghorn Therapeutics has a consensus target price of $12.13, suggesting a potential upside of 186.78%. Given Immix Biopharma's higher probable upside, equities research analysts plainly believe Immix Biopharma is more favorable than Foghorn Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immix Biopharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Foghorn Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.13

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are owned by institutional investors. 55.4% of Immix Biopharma shares are owned by company insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Foghorn Therapeutics had 11 more articles in the media than Immix Biopharma. MarketBeat recorded 13 mentions for Foghorn Therapeutics and 2 mentions for Immix Biopharma. Foghorn Therapeutics' average media sentiment score of 0.04 beat Immix Biopharma's score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immix Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Foghorn Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Immix Biopharma has higher earnings, but lower revenue than Foghorn Therapeutics. Immix Biopharma is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immix BiopharmaN/AN/A-$15.43M-$0.70-3.49
Foghorn Therapeutics$22.60M10.43-$98.43M-$1.36-3.11

Immix Biopharma has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.13, suggesting that its stock price is 213% more volatile than the S&P 500.

Summary

Foghorn Therapeutics beats Immix Biopharma on 12 of the 18 factors compared between the two stocks.

Get Immix Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMMX vs. The Competition

MetricImmix BiopharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$68.02M$6.49B$5.33B$8.43B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-2.879.1226.8519.75
Price / SalesN/A256.15388.74118.67
Price / CashN/A65.8538.2534.62
Price / Book3.016.436.764.50
Net Income-$15.43M$144.21M$3.23B$248.32M
7 Day Performance16.75%2.25%1.71%0.48%
1 Month Performance42.69%4.39%11.16%13.08%
1 Year Performance13.49%-2.71%17.17%7.36%

Immix Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMMX
Immix Biopharma
1.9419 of 5 stars
$2.41
+15.3%
$7.00
+190.5%
-9.1%$67.18MN/A-2.849News Coverage
High Trading Volume
FHTX
Foghorn Therapeutics
2.4784 of 5 stars
$4.21
-5.0%
$12.13
+188.0%
-34.7%$234.67M$22.60M-2.19120Analyst Revision
PROK
ProKidney
1.8129 of 5 stars
$0.80
-0.8%
$5.00
+525.2%
-79.2%$234.10M$76,000.00-1.453Analyst Upgrade
Gap Down
ADCT
ADC Therapeutics
2.6865 of 5 stars
$2.34
+23.8%
$7.75
+231.2%
-47.6%$232.08M$70.84M-0.98310Analyst Revision
High Trading Volume
RZLT
Rezolute
2.6258 of 5 stars
$3.80
+6.4%
$12.14
+219.5%
+33.7%$230.03MN/A-3.1140Analyst Downgrade
Analyst Revision
ANNX
Annexon
1.8657 of 5 stars
$2.09
+4.0%
$12.50
+498.1%
-59.0%$229.30MN/A-1.9960Gap Down
NVCT
Nuvectis Pharma
2.2081 of 5 stars
$10.95
+10.9%
$17.00
+55.3%
+65.3%$228.79MN/A-9.448Positive News
AARD
Aardvark Therapeutics
N/A$10.43
+5.5%
$31.25
+199.6%
N/A$226.29MN/A0.0018Analyst Downgrade
Analyst Revision
Gap Up
AMRN
Amarin
0.3615 of 5 stars
$10.90
+3.0%
$7.00
-35.8%
-38.8%$225.73M$214.11M-121.11360
MNPR
Monopar Therapeutics
2.8933 of 5 stars
$36.90
-0.7%
$55.33
+50.0%
+1,063.8%$225.64MN/A-18.7310News Coverage
Positive News
Analyst Upgrade
DRUG
Bright Minds Biosciences
3.0207 of 5 stars
$31.99
-3.1%
$83.25
+160.2%
+2,394.3%$225.34MN/A-188.17N/APositive News
Earnings Report
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:IMMX) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners